These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1259 related items for PubMed ID: 12679407

  • 1. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH.
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [Abstract] [Full Text] [Related]

  • 2. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH.
    Cancer Res; 2000 Sep 15; 60(18):5237-43. PubMed ID: 11016653
    [Abstract] [Full Text] [Related]

  • 3. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB.
    Cancer Res; 1999 Jul 01; 59(13):3192-8. PubMed ID: 10397265
    [Abstract] [Full Text] [Related]

  • 4. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
    Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH.
    Prostate; 2004 Feb 01; 58(2):145-55. PubMed ID: 14716739
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ.
    Prostate Cancer Prostatic Dis; 2002 Feb 01; 5(1):36-46. PubMed ID: 15195129
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
    Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS.
    J Nucl Med; 2010 Aug 01; 51(8):1293-300. PubMed ID: 20660376
    [Abstract] [Full Text] [Related]

  • 11. Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution.
    Tolmachev V, Malmberg J, Estrada S, Eriksson O, Orlova A.
    Int J Oncol; 2014 Jun 01; 44(6):1998-2008. PubMed ID: 24718894
    [Abstract] [Full Text] [Related]

  • 12. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
    Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR.
    J Nucl Med; 2008 Jul 01; 49(7):1066-74. PubMed ID: 18552139
    [Abstract] [Full Text] [Related]

  • 13. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
    Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, Holmes EH.
    Hybridoma; 2000 Jun 01; 19(3):249-57. PubMed ID: 10952413
    [Abstract] [Full Text] [Related]

  • 14. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M.
    J Nucl Med; 2015 Jun 01; 56(6):914-20. PubMed ID: 25883127
    [Abstract] [Full Text] [Related]

  • 15. 111In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues.
    Banerjee SR, Foss CA, Horhota A, Pullambhatla M, McDonnell K, Zale S, Pomper MG.
    Biomacromolecules; 2017 Jan 09; 18(1):201-209. PubMed ID: 28001364
    [Abstract] [Full Text] [Related]

  • 16. Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.
    Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K.
    J Nucl Med; 2017 Mar 09; 58(3):425-431. PubMed ID: 27789722
    [Abstract] [Full Text] [Related]

  • 17. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M, van Weerden WM.
    J Nucl Med; 2015 Jul 09; 56(7):1094-9. PubMed ID: 25977460
    [Abstract] [Full Text] [Related]

  • 18. The utility of monoclonal antibodies in the imaging of prostate cancer.
    Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith SJ.
    Semin Urol Oncol; 2002 Aug 09; 20(3):211-8. PubMed ID: 12215974
    [Abstract] [Full Text] [Related]

  • 19. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA.
    Cancer Res; 2000 Nov 01; 60(21):6095-100. PubMed ID: 11085533
    [Abstract] [Full Text] [Related]

  • 20. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
    Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S.
    J Nucl Med; 2014 Jan 01; 55(1):107-14. PubMed ID: 24337602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.